Aprea Therapeutics (NASDAQ:APRE) Receives “Buy” Rating from HC Wainwright

Aprea Therapeutics (NASDAQ:APRE)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a research note issued on Tuesday,Benzinga reports. They presently have a $20.00 price objective on the stock.

Aprea Therapeutics Trading Down 7.8 %

Aprea Therapeutics stock opened at $3.08 on Tuesday. The company has a fifty day simple moving average of $3.45 and a 200 day simple moving average of $3.56. Aprea Therapeutics has a 1-year low of $2.15 and a 1-year high of $8.85. The company has a market cap of $16.74 million, a P/E ratio of -1.10 and a beta of 0.88.

Aprea Therapeutics (NASDAQ:APRE) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.64) EPS for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.11. Aprea Therapeutics had a negative net margin of 1,029.50% and a negative return on equity of 57.86%. The company had revenue of $0.35 million during the quarter, compared to the consensus estimate of $0.45 million. On average, equities research analysts forecast that Aprea Therapeutics will post -2.55 EPS for the current year.

Insider Activity

In other Aprea Therapeutics news, Director Bernd R. Seizinger purchased 10,000 shares of the company’s stock in a transaction dated Friday, October 11th. The stock was bought at an average cost of $2.68 per share, for a total transaction of $26,800.00. Following the completion of the transaction, the director now owns 44,730 shares in the company, valued at approximately $119,876.40. This represents a 28.79 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, Director Marc Duey acquired 30,000 shares of the stock in a transaction on Wednesday, October 16th. The shares were bought at an average price of $4.39 per share, for a total transaction of $131,700.00. Following the purchase, the director now owns 240,113 shares in the company, valued at approximately $1,054,096.07. This trade represents a 14.28 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have purchased 42,290 shares of company stock valued at $165,096 over the last ninety days. 12.80% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Aprea Therapeutics

An institutional investor recently bought a new position in Aprea Therapeutics stock. Dimensional Fund Advisors LP acquired a new stake in shares of Aprea Therapeutics, Inc. (NASDAQ:APRE) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 11,071 shares of the company’s stock, valued at approximately $45,000. Dimensional Fund Advisors LP owned approximately 0.20% of Aprea Therapeutics at the end of the most recent reporting period. Hedge funds and other institutional investors own 34.19% of the company’s stock.

Aprea Therapeutics Company Profile

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.